Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Open-Label, Infusion Duration Study To Assess Safety, Tolerability and Efficacy of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

NCT04511702 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04511702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Open-Label, Infusion Duration Study To Assess Safety, Tolerability and Efficacy of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
October 2, 2020
Completion date
March 25, 2024
Enrollment
191 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

chronic uncontrolled gout, gout, uncontrolled gout